Gestalt Diagnostics
Founded Year
2015Stage
Series A | AliveTotal Raised
$12.63MLast Raised
$7.5M | 7 mos agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+385 points in the past 30 days
About Gestalt Diagnostics
Gestalt Diagnostics provides digital pathology solutions within the healthcare industry. The company offers a cloud-based digital pathology enterprise platform, PathFlow®, which is intended to improve the workflow of pathologists and assist in disease diagnosis. Gestalt's services are used by health systems, laboratories, hospitals, and developers focused on digital pathology. It was founded in 2015 and is based in Spokane, Washington.
Loading...
ESPs containing Gestalt Diagnostics
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The digital pathology for general diagnostics market refers to the use of digital imaging technology and computational tools to analyze and interpret pathology specimens for diagnostic purposes. Instead of using traditional glass slides, digital pathology involves digitizing tissue samples and creating high-resolution images that can be viewed and analyzed on computer screens. These digital images…
Gestalt Diagnostics named as Leader among 15 other companies, including Philips, Proscia, and Ibex.
Gestalt Diagnostics's Products & Differentiators
PathFlow
PathFlow is a cloud-based, AI-driven digital pathology enterprise platform designed to streamline workflows for pathologists. It supports professional, educational, and research modules, allowing customization to meet specific laboratory needs. The platform integrates with various scanners, electronic health records (EHRs), and laboratory information systems (LIS) using standards like HL7 and DICOM, ensuring interoperability.
Loading...
Research containing Gestalt Diagnostics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Gestalt Diagnostics in 1 CB Insights research brief, most recently on Oct 20, 2025.
Oct 20, 2025 report
Digital Health 50: The most promising digital health startups of 2025Expert Collections containing Gestalt Diagnostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Gestalt Diagnostics is included in 2 Expert Collections, including Digital Health.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Digital Health 50
50 items
Gestalt Diagnostics Patents
Gestalt Diagnostics has filed 5 patents.
The 3 most popular patent topics include:
- barcodes
- data management
- graphical control elements
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/10/2022 | 4/8/2025 | Medical testing equipment, Image processing, Digital photography, Microscopy, Computer vision | Grant |
Application Date | 5/10/2022 |
|---|---|
Grant Date | 4/8/2025 |
Title | |
Related Topics | Medical testing equipment, Image processing, Digital photography, Microscopy, Computer vision |
Status | Grant |
Latest Gestalt Diagnostics News
Oct 6, 2025
Introducing PathFlow Version 6 News provided by Share this article Share toX SPOKANE, Wash., Oct. 6, 2025 /PRNewswire/ -- Gestalt is proud to announce the release of PathFlow Version 6, the latest evolution of its award-winning digital pathology platform. This major update introduces a dynamic, high-powered field of view designed to elevate the diagnostic experience for pathologists, along with a dedicated tumor board workflow module that streamlines multidisciplinary collaboration, in addition to other features. PathFlow Version 6 delivers a robust visual interface that enables pathologists to navigate their images with greater precision, speed, and clarity—supporting complex case reviews and high-volume workflows without compromise. The enhanced field of view is optimized for performance across diverse specimen types, and in a manner that is familiar and comfortable to them. By providing pathologists with this embedded high-power field of view, they are able to standardize the quantitative assessment of specific cells or features within a tissue sample, which is essential for cancer diagnosis, tumor grading, and determining patient prognosis, ensuring diagnostic confidence every time. PathFlow Version 6 is built for the demands of modern pathology and the future of precision medicine. The newly developed tumor board module provides the focused workflow needs for supporting real-time collaboration across oncology teams, radiologists, and pathologists. With configurable workflows, secure data sharing, and the ability for both admins and pathologists to easily add, update and remove cases and images institutions can now conduct tumor board reviews with greater efficiency and clinical alignment. "This release reflects our commitment to empowering pathologists with tools that not only enhance diagnostic accuracy but also foster meaningful collaboration," said Lisa-Jean Clifford, President of Gestalt Diagnostics. "PathFlow Version 6 is built for the demands of modern pathology and the future of precision medicine." PathFlow V.6 is available immediately to existing customers and new partners seeking scalable, interoperable digital pathology solutions. It is being featured during DPA's Pathology Visions Conference in San Diego this week. Come to booth #600 for a personalized demonstration. Not going to Visions? Reach out for more information. About Gestalt Gestalt transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose diseases faster and more efficiently. Our PathFlow solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks, allowing them to focus on their expertise – providing invaluable experience where it matters most. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn SOURCE Gestalt Diagnostics
Gestalt Diagnostics Frequently Asked Questions (FAQ)
When was Gestalt Diagnostics founded?
Gestalt Diagnostics was founded in 2015.
Where is Gestalt Diagnostics's headquarters?
Gestalt Diagnostics's headquarters is located at 850 E. Spokane Falls Boulevard, Spokane.
What is Gestalt Diagnostics's latest funding round?
Gestalt Diagnostics's latest funding round is Series A.
How much did Gestalt Diagnostics raise?
Gestalt Diagnostics raised a total of $12.63M.
Who are the investors of Gestalt Diagnostics?
Investors of Gestalt Diagnostics include Kickstart Fund, Cowles Company, Tacoma Venture Fund, Inland Imaging, The Morningstar Foundation and 3 more.
Who are Gestalt Diagnostics's competitors?
Competitors of Gestalt Diagnostics include Paige and 2 more.
What products does Gestalt Diagnostics offer?
Gestalt Diagnostics's products include PathFlow and 2 more.
Loading...
Compare Gestalt Diagnostics to Competitors
Ibex specializes in AI-based cancer diagnostics within the healthcare technology sector. The company offers AI-powered diagnostic solutions that assist pathologists in providing accurate and efficient cancer diagnoses. Its solutions are developed using advanced algorithms and digital workflows to detect cancer with clinical-grade accuracy. It was founded in 2016 and is based in Tel Aviv, Israel.
Ellogon.AI provides a solution named EIDOS, which utilizes deep learning technology to assist medical experts in selecting suitable patients for immunotherapy by quantifying relevant biomarkers from histopathology images. The company operates within the healthcare sector, specifically targeting medical professionals involved in cancer treatment and research. It was founded in 2019 and is based in Amsterdam, Netherlands.
Alpenglow Biosciences focuses on drug development and clinical diagnostics using 3D imaging technology in the life sciences sector. The company provides sample preparation, open-top light-sheet microscopy, cloud-based processing and storage, 3D visualization, and AI analysis. Alpenglow's technology aims to enhance understanding of biological systems for pharmaceutical research. Alpenglow Biosciences was formerly known as Lightspeed Microscopy. It was founded in 2018 and is based in Seattle, Washington.
Nucleai focuses on spatial biology in precision medicine. The company provides artificial intelligence (AI)-powered image analysis applications to pharmaceutical companies and clinicians, enhancing drug development and supporting treatment decisions. It primarily serves the pharmaceutical industry. It was founded in 2018 and is based in Chicago, Illinois.
4D Path is a company that operates within the healthcare industry. They have developed a platform that measures and quantifies cell cycle deregulations and tumor microenvironment dynamics to predict patient responses to cancer therapies. Their technology provides biomarker profiling and stratification from histopathology images. It was founded in 2016 and is based in Newton Center, Massachusetts.
Mechanomind provides AI diagnostics for skin cancer within the healthcare technology sector. The company utilizes computer vision and deep learning to assist in the diagnosis of skin cancer, including the classification of skin tumor subtypes and offering decision support for pathologists. Mechanomind's technology is scanner and image quality agnostic, aimed at maintaining accuracy and efficiency in histopathology analysis. It was founded in 2015 and is based in New York, New York.
Loading...